Novartis considers selling ophthalmology, respiratory units to invest in cutting-edge medicines

Any sale of the ophthalmology and respiratory businesses is likely to begin in 2023, after the process for Sandoz is completed, the Bloomberg report said.;

Published On 2022-11-17 06:45 GMT | Update On 2022-11-17 07:23 GMT

Basel: Swiss drugmaker Novartis AG is considering selling its ophthalmology and respiratory units, a Bloomberg report said on Wednesday, citing people familiar with the matter.

The company is seeking to raise money from the possible sale of the assets to invest in cutting-edge medicines, the report said, adding that the ophthalmology unit could alone fetch about $5 billion.

The drugmaker declined to comment on the report.

Novartis in August said it was planning to spin off its generics unit Sandoz to sharpen its focus on its patented prescription medicines.

The company spun off its Alcon eye care business in 2019 and in November last year, agreed to sell a nearly one-third voting stake in Roche as it seeks to streamline operations.

Sandoz sales have been hurt by pricing pressure that has affected the broader generics industry for years, particularly in the United States, although the country accounts for less than a quarter of its total sales.

Any sale of the ophthalmology and respiratory businesses is likely to begin in 2023 after the process for Sandoz is completed, the Bloomberg report said.

Novartis has said that its five main therapeutic areas are cardio-renal care, immunology, neuroscience, oncology, and hematology and that it was taking an "opportunistic" development approach in ophthalmology and respiratory care.

The group's largest ophthalmology product is Lucentis to treat macular degeneration in the elderly, with revenue of 2.16 billion euros last year. Novartis partners with Roche on the medication.

But Lucentis' revenue is in decline because cheap copies are available. Novartis' next-generation macular degeneration drug Beovu has not been a commercial success because of concerns over potential side effects.

The Swiss group's respiratory and allergy sales were $2.1 billion last year, mostly from the asthma drug Xolair, where Roche is also a partner.

The two companies are testing Xolair, which is under threat from competing asthma products, as a food allergy treatment.

Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Novartis considers selling ophthalmology, respiratory units to invest in cutting-edge medicines

Any sale of the ophthalmology and respiratory businesses is likely to begin in 2023, after the process for Sandoz is completed, the Bloomberg report said.;

Similar News

Govt Panel Makes This Approval Mandatory For New Drug Licenses

CDSCO Panel Asks Glenmark To Justify BE Waiver for FDC Inhalation Suspension With Scientific Evidence

Sun Pharma Gets SEC Nod to Begin Phase III Trial of Cough Drug Gefapixant

USFDA grants priority review for Winrevair label update based on ZENITH Trial: Merck

AstraZeneca, Summit in discussions over USD 15 billion cancer drug licensing deal: Report

Bain Capital divests 2.4 percent stake in Emcure Pharma for Rs 563 crore

Shilpa Pharma Lifesciences Unit-1 successfully completes GMP inspection from Brazilian regulatory authority

Lupin rolls out Nasal spray for rhinorrhea relief in US